The MAP3K TAK1: a chock block to liver cancer formation

Affiliations

¹ Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, Department of Surgery, Division of Transplantation University of California San Francisco San Francisco, CA, USA.

Comment

Yann Malato et al. Hepatology. 2010 Oct.

. 2010 Oct;52(4):1506-9.

doi: 10.1002/hep.23878.

¹ Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, Department of Surgery, Division of Transplantation University of California San Francisco San Francisco, CA, USA.

No abstract available

Comment on

Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis.
Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. Inokuchi S, et al. Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):844-9. doi: 10.1073/pnas.0909781107. Epub 2009 Dec 18. Proc Natl Acad Sci U S A. 2010. PMID: 20080763 Free PMC article.
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer.
Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Müller M, de Vos R, Wolf MJ, Boege Y, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akira S, Tacke F, Heikenwalder M, Trautwein C, Luedde T. Bettermann K, et al. Cancer Cell. 2010 May 18;17(5):481-96. doi: 10.1016/j.ccr.2010.03.021. Cancer Cell. 2010. PMID: 20478530